Carazolol
 | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
| CAS Number | 57775-29-8 |
| ATCvet code | QC07AA90 (WHO) |
| PubChem | CID 71739 |
| IUPHAR/BPS | 569 |
| ChemSpider | 64783 |
| UNII |
29PW75S82A  |
| ChEMBL | CHEMBL324665 |
| Chemical data | |
| Formula | C18H22N2O2 |
| Molar mass | 298.38 |
| |
Carazolol is a high affinity antagonist/partial inverse agonist (also referred to as a beta blocker) of the β-adrenergic receptor.[1]
References
- ↑ Innis RB, Corrēa FM, Synder SH (1979). "Carazolol, an extremely potent beta-adrenergic blocker: binding to beta-receptors in brain membranes". Life Sci. 24 (24): 2255–64. doi:10.1016/0024-3205(79)90102-4. PMID 41147.
External links
- Carazolol at the US National Library of Medicine Medical Subject Headings (MeSH)
This article is issued from Wikipedia - version of the Tuesday, April 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.